Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 2/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17134615 | 0.88 | RAPGEF4 (0.44) | RAPGEF4PTGS2MAPTLMNAALDH1A1 | |
| SCHEMBL17134774 | 0.88 | RAPGEF4 (0.48) | RAPGEF4PTGS2MAPTLMNAALDH1A1 | |
| SCHEMBL17135279 | 0.85 | MAPT (0.41) | RAPGEF4PTGS2MAPTLMNAALDH1A1 | |
| SCHEMBL17135316 | 0.85 | MAPT (0.41) | RAPGEF4PTGS2MAPTLMNAALDH1A1 | |
| SCHEMBL17156862 | 0.82 | LMNA (0.45) | RAPGEF4MAPTLMNAALDH1A1MEN1 | |
| SCHEMBL17134974 | 0.79 | EGFR (0.54) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL17156800 | 0.77 | NR4A2 (0.48) | RAPGEF4PTGS2LMNAALDH1A1MEN1 | |
| SCHEMBL1341369 | 0.77 | MAP2K1 (0.53) | PTGS2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL1340735 | 0.75 | MAP2K1 (0.51) | CSF1RMAP2K1NUDT1 | |
| SCHEMBL17134934 | 0.75 | PTGS2 (0.50) | PTGS2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2927214-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9701689-B2 | Substituted pyridines and pyridazines as CCR10 receptor inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-07-11 | — | — | US | disclosed |
| US-20150299214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2927214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | ARG1, H1-0, TYR | RAPGEF4 4515/4885PTGS2 3410/4885MAPT 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.